Lipocine Inc (LPCN) FinancialsLPCNLipocine Inc

Evaluating the bottom line, Lipocine Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is -29.09%. These profitability ratios, combined with a Return on Equity (ROE) of -52.86%, provide a clear picture of how effectively LPCN converts its operational activities into shareholder value.

In the context of the broader market, LPCN competes directly with industry leaders such as ATYR and RKTO. With a market capitalization of $13.02M, it holds a significant position in the sector. When comparing efficiency, LPCN's gross margin of N/A stands against ATYR's N/A and RKTO's N/A. Such benchmarking helps identify whether Lipocine Inc is trading at a premium or discount relative to its financial performance.

Lipocine's total revenue for Q3 2026 was $2.29 million, but it reported a net income loss of $666,192, reflecting ongoing financial challenges. The gross margin remains strong at 100% for prior quarters, but recent performance shows a decline in revenue generation.